多病毒蛋白衰减突变的重组狂犬病活疫苗株的构建、鉴定及其在犬中的效力评价
研究通过反向遗传学系统构建了在核蛋白N273/394和糖蛋白G194/333引入衰减突变的狂犬病活疫苗候选株ERA-NG2,在小鼠和犬中评估其安全性和免疫原性。ERA-NG2在鼠脑内接种不引起临床症状,传代后保留除N394外的突变及高度衰减表型;犬单次肌注后诱导病毒中和抗体反应且无临床症状。
要点
- ERA-NG2在核蛋白N273/394和糖蛋白G194/333引入衰减突变。
- 小鼠脑内接种ERA-NG2不引起临床症状,传代后保留高度衰减表型。
- 犬单次肌注ERA-NG2诱导病毒中和抗体反应且无临床症状。
核心结论
- ERA-NG2在犬中具有高安全性和实质性免疫原性,是有助于犬类接种的有前景的活疫苗候选株。
研究设计与样本
- 通过反向遗传学系统构建在N273/394和G194/333引入衰减突变的狂犬病活疫苗候选株ERA-NG2,并在小鼠和犬中评估安全性和免疫原性。
主要发现
- ERA-NG2在鼠脑内接种后未引起任何临床症状。
- ERA-NG2在乳鼠脑内传10代后,除N394位点突变外保留所有引入的突变及高度衰减表型。
- ERA-NG2在小鼠中诱导病毒中和抗体反应和保护性免疫。
- 犬在所有测试剂量下,ERA-NG2均诱导病毒中和抗体反应且未引起任何临床症状。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Live rabies vaccines have advantageous features that can facilitate mass vaccination for dogs, the most important reservoirs/transmitters of rabies. However, some live vaccine strains have problems in their safety, namely, risks from the residual pathogenicity and the pathogenic reversion of live vaccine strains. The reverse genetics system of rabies virus provides a feasible option to improve the safety of a live vaccine strain by, for example, artificially introducing attenuating mutations into multiple viral proteins. It was previously demonstrated in separate studies that introduction of amino acid residues Leu at position 333 in the viral glycoprotein (G333), Ser at G194, and Leu/His at positions 273/394 in the nucleoprotein (N273/394) enhance the safety of a live vaccine strain. In this study, to test our hypothesis that combinational introduction of these residues would significantly increase the safety level of a vaccine strain, we generated a novel live vaccine candidate, ERA-NG2, that is attenuated by mutations at N273/394 and G194/333, and we examined its safety and immunogenicity in mice and dogs. ERA-NG2 did not cause any clinical signs in mice after intracerebral inoculation. After 10 passages in suckling mouse brains, ERA-NG2 retained all of the introduced mutations except the mutation at N394 and the highly attenuated phenotype. These findings indicate that the ERA-NG2 is highly and stably attenuated. After confirming that ERA-NG2 induced a virus-neutralizing antibody (VNA) response and protective immunity in mice, we immunized dogs intramuscularly with a single dose (105-7 focus-forming units) of ERA-NG2 and found that, at all of the tested doses, the strain induced a VNA response in dogs without inducing any clinical signs. These findings demonstrate that ERA-NG2 has a high level of safety and a substantial level of immunogenicity in dogs and thus is a promising live vaccine candidate that can facilitate vaccination in dogs.
引用
- Izumi F, Miyamoto S, Masatani T, et al. Generation and characterization of a genetically modified live rabies vaccine strain with attenuating mutations in multiple viral proteins and evaluation of its potency in dogs. Vaccine. 2023. PMID: 37400284. doi:10.1016/j.vaccine.2023.06.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。